Withdrawal symptoms in critically ill children after long-term administration of sedatives and/or analgesics: A first evaluation*
- 1 August 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 36 (8), 2427-2432
- https://doi.org/10.1097/ccm.0b013e318181600d
Abstract
To establish frequencies of benzodiazepine and opioid withdrawal symptoms, and correlations with total doses and duration of administration. A prospective, repeated-measures design. Two pediatric intensive care units in a university children’s hospital. Seventy-nine children, aged 0 days to 16 yrs, who received intravenous midazolam and/or opioids for >5 days. None. Pediatric intensive care unit nurses assessed withdrawal symptoms using the Sophia Benzodiazepine and Opioid Withdrawal Checklist, which includes all withdrawal symptoms (n = 24) described in the pediatric literature. Over 6 months, 2188 observations in 79 children were recorded. Forty-two percent of observations were performed within 24 hrs after tapering off or discontinuation of medication. Symptoms representing overstimulation of the central nervous system, such as anxiety, agitation, grimacing, sleep disturbance, increased muscle tension, and movement disorder, were observed in >10% of observations. Of symptoms reflecting gastrointestinal dysfunction, diarrhea and gastric retention were most frequently observed. Tachypnea, fever, sweating, and hypertension as manifestations of autonomic dysfunction were observed in >13% of observations. The Spearman’s rank-correlation coefficient between total doses of midazolam and maximum sum score (of the Sophia Benzodiazepine and Opioid Withdrawal Checklist) was .51 (p < 0.001). The correlation between total doses of opioids and the maximum sum score was .39 (p < 0.01). A significant correlation (.52; p < 0.001) was also found between duration of use and maximum sum score. This is the first study to report frequencies of all 24 withdrawal symptoms observed in children after decrease or discontinuation of benzodiazepines and/or opioids. Agitation, anxiety, muscle tension, sleeping <1 hr, diarrhea, fever, sweating, and tachypnea were observed most frequently. Longer duration of use and high dosing are risk factors for development of withdrawal symptoms in children.This publication has 35 references indexed in Scilit:
- A Prospective Evaluation of Opioid Weaning in Opioid-Dependent Pediatric Critical Care PatientsAnesthesia & Analgesia, 2006
- Paradoxical reaction following intravenous midazolam premedication in pediatric patients – a randomized placebo controlled trial of ketamine for rapid tranquilizationPediatric Anesthesia, 2004
- Managing sedation withdrawal in children who undergo prolonged PICU admission after discharge to the wardPediatric Anesthesia, 2004
- The provision of analgesia and sedation in the PICU: current practice and recent advancesPediatric Anesthesia, 2002
- Recollection of children following intensive careArchives of Disease in Childhood, 2000
- Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unitIntensive Care Medicine, 1994
- Optimal sedation of mechanically ventilated pediatric critical care patientsCritical Care Medicine, 1994
- Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administrationThe Journal of Pediatrics, 1991
- Movement disorder after withdrawal of fentanyl infusionThe Journal of Pediatrics, 1991
- Acute Benzodiazepine Withdrawal Syndrome After Midazolam Infusions in ChildrenCritical Care Medicine, 1989